Skip to content
Biodatica
Start free

BeOne Medicines

Duarte, California

OncologyPhase IIIListed · ONC

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

4d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jun 23, 2026

    Myeloid Malignancy · RECRUITING · sponsor: BeOne Medicines · An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

    ClinicalTrials.gov · NCT07619287 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jun 17, 2026

    Healthy Volunteers · RECRUITING · sponsor: BeOne Medicines · A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults

    ClinicalTrials.gov · NCT07628881 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Jun 5, 2026

    Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer · RECRUITING · sponsor: BeOne Medicines · A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

    ClinicalTrials.gov · NCT07652736 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Jun 11, 2025

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · RECRUITING · sponsor: BeOne Medicines · A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    ClinicalTrials.gov · NCT06943872 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    May 29, 2025

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: BeOne Medicines · A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

    ClinicalTrials.gov · NCT06970743 (opens the source filing in a new tab)

  6. Trial

    PHASE3 registered

    Apr 10, 2025

    CLL, Chronic Lymphocytic Leukemia · RECRUITING · sponsor: BeOne Medicines · A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    ClinicalTrials.gov · NCT06846671 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Mar 18, 2025

    Advanced Solid Tumor, Metastatic Solid Tumor · RECRUITING · sponsor: BeOne Medicines · A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT06803680 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Mar 5, 2025

    Mantle Cell Lymphoma, B Cell Lymphoma · RECRUITING · sponsor: BeOne Medicines · A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

    ClinicalTrials.gov · NCT06742996 (opens the source filing in a new tab)

  9. Trial

    PHASE1 registered

    Feb 4, 2025

    Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer · RECRUITING · sponsor: BeOne Medicines · BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

    ClinicalTrials.gov · NCT06756932 (opens the source filing in a new tab)

  10. Trial

    PHASE1/PHASE2 registered

    Nov 27, 2024

    B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma · RECRUITING · sponsor: BeOne Medicines · A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

    ClinicalTrials.gov · NCT06634589 (opens the source filing in a new tab)

  11. Trial

    PHASE1 registered

    Jul 23, 2024

    Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer · RECRUITING · sponsor: BeOne Medicines · A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT06427941 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Dec 1, 2023

    Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer · RECRUITING · sponsor: BeOne Medicines · BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    ClinicalTrials.gov · NCT06120283 (opens the source filing in a new tab)

  13. Trial

    PHASE2 registered

    Oct 23, 2023

    Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory · ACTIVE_NOT_RECRUITING · sponsor: BeOne Medicines · A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

    ClinicalTrials.gov · NCT05952037 (opens the source filing in a new tab)

  14. Trial

    PHASE1 registered

    Sep 21, 2023

    Advanced Solid Tumor, Solid Tumor · RECRUITING · sponsor: BeOne Medicines · A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT05981703 (opens the source filing in a new tab)

  15. Trial

    PHASE1 registered

    Jun 20, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma · TERMINATED · sponsor: BeOne Medicines · A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

    ClinicalTrials.gov · NCT05828589 (opens the source filing in a new tab)

  16. Trial

    PHASE2/PHASE3 registered

    Apr 17, 2023

    Primary Membranous Nephropathy · ACTIVE_NOT_RECRUITING · sponsor: BeOne Medicines · A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

    ClinicalTrials.gov · NCT05707377 (opens the source filing in a new tab)

  17. Trial

    PHASE3 registered

    Mar 10, 2022

    Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: BeOne Medicines · A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

    ClinicalTrials.gov · NCT05100862 (opens the source filing in a new tab)

  18. Trial

    PHASE1/PHASE2 registered

    Sep 13, 2021

    B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma · RECRUITING · sponsor: BeOne Medicines · A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

    ClinicalTrials.gov · NCT05006716 (opens the source filing in a new tab)

  19. Trial

    PHASE1/PHASE2 registered

    May 24, 2021

    Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm · RECRUITING · sponsor: BeOne Medicines · A Study of BGB-11417 in Participants With Myeloid Malignancies

    ClinicalTrials.gov · NCT04771130 (opens the source filing in a new tab)

  20. Trial

    PHASE3 registered

    Dec 19, 2019

    Advanced Malignancies · COMPLETED · sponsor: BeOne Medicines · Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

    ClinicalTrials.gov · NCT04164199 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources